Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant cyclophosphamide after thiotepa-based haplo-identical HSCT for relapsed-refractory lymphoma
DRKS00009880Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in non-Hodgkin lymphoma (NHL), sponsored by Heidelberg University Hospital. Started Nov 2016; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on DRKS00009880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00009880.